Navigation Links
Titanium Group to Showcase Products and Technologies in Prestigious Government Seminar
Date:11/13/2007

sts and to meet its liquidity and other financing needs; (e) the declaration and payment of dividends; and (f) the Company's ability to respond to changes in customer demand and regulations. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. When issued in this report, the words "expects," "anticipates," "intends, " "plans," "believes," "seeks," "estimates," and similar expressions are generally intended to identify forward-looking statements.

Important factors that could cause the actual results to differ materially from those in the forward-looking statements include, among other items, (i) changes in the regulatory and general economic environment; (ii) conditions in the capital markets, including the interest rate environment and the availability of capital; (iii) changes in the competitive marketplace that could affect the Company's revenue and/or cost and expenses, such as increased competition, lack of qualified marketing, management or other personnel, and increased labor and inventory costs; (iv) changes in technology or customer requirements, which could render the Company's technologies noncompetitive or obsolete; (v) new product introductions, product sales mix and the geographic mix of sales.

The Company disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this advertisement are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, governmental approval processes, the impact of competitive products or pricing, technological cha
'/>"/>

SOURCE Titanium Group, Ltd
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4

Related biology news :

1. Titanium Group Announces Contract With Haitong Securities
2. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
3. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
4. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
5. Coal-based fuels and products hit the refinery
6. Researchers develop simple method to create natural drug products
7. NIH awards UC $9 million grant to improve patient point-of-care technologies
8. Patent Issued for e-Smart Technologies, Inc.s First Biometric Match-on-Card Technology
9. RSC Project Prospect scoops prestigious award
10. UC Riverside biologist receives prestigious MacArthur Fellowship
11. CIC Again Named to Software Magazines Annual Prestigious Software 500 List
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Copying mother nature's designs 2China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS 14257 1China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS 14257 2China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS 14257 3China Biologic Products Enters into a Strategic Research and Development Agreement with IBT of CAMS 14257 4Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 14255 1Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 14255 2Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 14255 3Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 14255 4Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 14255 5Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 14255 6Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009 14255 7Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 1Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 2Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 3Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 4Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 5Neogen Reports 18 25 Increase in Net Income 12 25 Increase in Revenues 14253 6